<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00494663</url>
  </required_header>
  <id_info>
    <org_study_id>DIO-502</org_study_id>
    <nct_id>NCT00494663</nct_id>
  </id_info>
  <brief_title>A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes</brief_title>
  <official_title>A Phase 2b, Randomized, Double-Blind, Parallel-Group, Study of Safety and Efficacy of 16 Weeks of Treatment With DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo in Subjects With Type 2 Diabetes Mellitus (Protocol No. DIO-502)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DiObex</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DiObex</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DiObex Inc. is developing an experimental drug (DIO-902) that is made up of part of the&#xD;
      ketoconazole molecule for the treatment of elevated blood glucose associated with type 2&#xD;
      diabetes mellitus. Ketoconazole (NizoralÂ®) is a drug available by prescription for the&#xD;
      treatment of fungal infections however DIO-902 is an investigational drug. DIO-902 may lower&#xD;
      blood glucose by lowering levels of a naturally occurring hormone called cortisol. Elevated&#xD;
      cortisol may contribute to the development of type 2 diabetes.&#xD;
&#xD;
      The purpose of this research study is to test the safety of DIO-902 when taken by mouth with&#xD;
      metformin and the cholesterol-lowering drug atorvastatin to determine the type and severity&#xD;
      of any side effects from this treatment.&#xD;
&#xD;
      Other purposes of the study are to see how the treatment affects your blood glucose levels,&#xD;
      cholesterol levels, blood pressure, and waist circumference.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DIO-902 may lower blood glucose by lowering levels of a naturally occurring hormone called&#xD;
      cortisol. Elevated cortisol may contribute to the development of type 2 diabetes. Clinical&#xD;
      trials with ketoconazole have been carried out in patients with type 2 diabetes. Three&#xD;
      clinical trials with DIO-902 have been completed in which 37 patients with type 2 diabetes&#xD;
      and 42 normal healthy volunteers (people without type 2 diabetes) were enrolled. Patients in&#xD;
      these studies received multiple doses of DIO-902. DIO-902 may reduce the level of cortisol in&#xD;
      your blood and therefore may provide you with better control of your blood glucose levels.&#xD;
&#xD;
      STUDY DRUG ASSIGNMENT&#xD;
&#xD;
      You will be randomized, that is, given a 1 in 4 chance of receiving either 150mg/day of&#xD;
      DIO-902, 300mg/day of DIO-902, 450mg/day of DIO-902 or DIO-902 placebo and a 1 in 2 chance of&#xD;
      receiving 10mg/day of atorvastatin or atorvastatin placebo. The study drug is a tablet and&#xD;
      will be taken by mouth with water. You will take 3 tablets of DIO-902 or DIO-902 placebo and&#xD;
      1 tablet of atorvastatin or atorvastatin placebo each day. The tablets will be taken at the&#xD;
      same time each day (2200h or 10:00pm). Neither you nor your doctor will know which dose of&#xD;
      DIO-902 or DIO-902 placebo you are on or whether you are taking the atorvastatin or&#xD;
      atorvastatin placebo. If necessary, your doctor has a way of finding out which dose you were&#xD;
      assigned.&#xD;
&#xD;
      Atorvastatin&#xD;
&#xD;
      If you are taking any cholesterol-lowering drugs, these drugs must be discontinued on the day&#xD;
      prior to the Pre-Treatment Visit (Week -4) and for the duration of the study. At Visit 1&#xD;
      (Week 0) you will be assigned to DIO-902 or DIO-902 placebo and to either atorvastatin or&#xD;
      atorvastatin placebo. You will continue to take the assigned drug until Study Visit 4 (Week&#xD;
      8). At Study Visit 4 (Week 8) all patients will begin taking atorvastatin through the&#xD;
      remainder of the study. Your DIO-902 or DIO-902 placebo assignment will remain the same.&#xD;
      Atorvastatin tablets will be supplied to you until Study Visit 6 (Week 16). At this visit you&#xD;
      will be given a prescription for a 28 day supply of atorvastatin 10mg.day to last until Study&#xD;
      Visit 7 (Week 20).&#xD;
&#xD;
      There will a total of 9 study visits. At each visit all or some of the following will occur:&#xD;
      blood and urine samples will be taken, physical exam, assessment of side effects, and ECG&#xD;
      will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Program Terminated&#xD;
  </why_stopped>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">December 2008</completion_date>
  <primary_completion_date type="Anticipated">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. The primary efficacy endpoint will be change from baseline to the end of treatment (Study Visit 6, Week 16) in HbA1c</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Change from baseline to Week 8 in total and LDL-cholesterol (LDL-C) 2. Change from baseline to the end of treatment (Week 16) in the following : Seated blood pressure (systolic, diastolic and mean arterial pressure) Fasting blood glucose</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150mg DIO-902 + 10mg atorvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg DIO-902 + 10mg atorvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>450mg DIO-902 + 10mg atorvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>DIO-902 Placebo + 10mg atorvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150mg DIO-902 + atorvastatin placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg DIO-902 + atorvastatin placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>450mg DIO-902 + atorvastatin placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>DIO-902 placebo + atorvastatin placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DIO-902</intervention_name>
    <description>150mg tablet once per day for 16 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>2S,4R enantionmer of ketoconazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DIO-902</intervention_name>
    <description>300mg tablet once per day for 16 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>2S,4R enantiomer of ketoconazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DIO-902</intervention_name>
    <description>450mg DIO-902 tablet once daily for 16 weeks</description>
    <arm_group_label>3</arm_group_label>
    <other_name>2S,4R enantiomer of ketoconazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DIO-902 placebo</intervention_name>
    <description>DIO-902 placebo tablet once daily for 16 weeks</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DIO-902</intervention_name>
    <description>150mg tablet of DIO-902 once daily for 16 weeks</description>
    <arm_group_label>5</arm_group_label>
    <other_name>2S,4R enantiomer of ketoconazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DIO-902</intervention_name>
    <description>300mg DIO-902 tablet daily for 16 weeks</description>
    <arm_group_label>6</arm_group_label>
    <other_name>2S,4R enantiomer of ketoconazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DIO-902</intervention_name>
    <description>450mg DIO-902 tablet for 16 weeks</description>
    <arm_group_label>7</arm_group_label>
    <other_name>2S,4R enantiomer of ketoconazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DIO-902 placebo</intervention_name>
    <description>DIO-902 placebo tablet once daily for 16 weeks</description>
    <arm_group_label>8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        A subject may be included in this study if he/she meets all of the following criteria:&#xD;
&#xD;
          1. Male or female, age 18 to 75&#xD;
&#xD;
          2. Females of childbearing potential (intact uterus and within 1 year since the last&#xD;
             menstrual period) should be non-lactating and have a negative serum pregnancy test. In&#xD;
             addition, these subjects should agree to use the following acceptable birth control&#xD;
             methods beginning at the Screening Visit and throughout the study:&#xD;
&#xD;
               1. abstinence&#xD;
&#xD;
               2. surgical sterilization (bilateral tubal ligation, hysterectomy, bilateral&#xD;
                  oophorectomy) 6 months minimum&#xD;
&#xD;
               3. IUD in place for at least 3 months&#xD;
&#xD;
               4. barrier methods (condom or diaphragm) with spermicide&#xD;
&#xD;
               5. surgical sterilization of the partner (vasectomy for 6 months)&#xD;
&#xD;
               6. hormonal contraceptives for at least 3 months prior to the first dose&#xD;
&#xD;
          3. Diagnosis of type 2 diabetes mellitus (DM) for at least 6 months.&#xD;
&#xD;
          4. Type 2 diabetes may be treated only with metformin (metformin hydrochloride tablets or&#xD;
             metformin hydrochloride extended-release tablets) at a total daily dose of 500 mg to&#xD;
             the maximum labeled dose. (See Appendix G for List of Drug Trade Names).The dose of&#xD;
             metformin must be stable for &gt;8 weeks prior to the Pre-Treatment Visit (Week -4) and&#xD;
             throughout the course of the study. The subject must not be on any other pharmacologic&#xD;
             or over-the-counter treatments for diabetes.&#xD;
&#xD;
          5. HbA1C level of 7.0 to 10.0%&#xD;
&#xD;
          6. Fasting C-peptide level of &gt;0.33 nmol/l (1.0 ng/ml)&#xD;
&#xD;
          7. ACTH stimulation test results with any cortisol level of &gt;18 Âµg/dl at baseline or 60&#xD;
             minutes&#xD;
&#xD;
          8. Normal complete blood count (CBC) with platelets and differential&#xD;
&#xD;
          9. 12-lead electrocardiogram (ECG) shows no acute ischemia or clinically significant&#xD;
             abnormality. Subjects with QTc interval of &gt;450 msec will be excluded from the study.&#xD;
&#xD;
         10. BMI of 27 to 42 kg/m2 (see Appendix B)&#xD;
&#xD;
         11. Subjects with a history of hypertension may be on a stable anti-hypertensive regimen&#xD;
             for (except those drugs stated under Exclusion Criterion 8) for &gt;6 weeks prior to the&#xD;
             Pre-Treatment Visit (Week -4))&#xD;
&#xD;
         12. Ability to comprehend and a willingness to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A subject may be excluded from this study if he/she meets any of the following&#xD;
             criteria:&#xD;
&#xD;
               1. Previous participation in a clinical trial with DIO-902.&#xD;
&#xD;
               2. History of any atherosclerotic disorder (myocardial infarction, unstable angina,&#xD;
                  cerebrovascular accident, peripheral vascular disease or congestive heart failure&#xD;
                  secondary to ischemic myocardial injury) that would, in the estimation of the&#xD;
                  Investigator, make it unsafe to stop all lipid lowering drugs for up to 12 weeks&#xD;
                  during the course of the study.&#xD;
&#xD;
               3. Known hypersensitivity or idiosyncratic reaction related to ketoconazole or other&#xD;
                  imidazole compounds.&#xD;
&#xD;
               4. History of malignancy (except basal cell carcinoma) within the 3 years before the&#xD;
                  initial dose of the study medication.&#xD;
&#xD;
               5. Excessive alcohol intake (&gt;20 g per day for females (1.5 standard alcohol drinks)&#xD;
                  or &gt;30 g per day for males (2.0 standard alcohol drinks) (a standard drink&#xD;
                  contains 14 g of alcohol: 12 oz of beer, 5 oz of wine or 1.5 oz of spirits) or&#xD;
                  drug abuse. (1.0 fluid oz (US) = 29.57 ml)&#xD;
&#xD;
               6. Any other clinically significant medical condition, as determined by the&#xD;
                  Investigator. These clinically significant medical conditions include, but are&#xD;
                  not limited to, uncontrolled hypertension, NYHA class III or IV CHF,&#xD;
                  proliferative diabetic retinopathy and neuropathic symptoms that limit activities&#xD;
                  of daily living.&#xD;
&#xD;
               7. Participation in another clinical trial and/or treatment received with any&#xD;
                  investigational agent within one month before the initial dose of study&#xD;
                  medication.&#xD;
&#xD;
               8. Concomitant therapy with the following: (See Appendix G for List of Drug Trade&#xD;
                  Names)&#xD;
&#xD;
                    1. weight loss medications&#xD;
&#xD;
                    2. oral or injected hypoglycemics (metformin is allowed) or insulin&#xD;
&#xD;
                    3. oral, parenteral or inhaled steroids; nasal, topical ocular, intravitreal,&#xD;
                       and low to moderate potency topical steroids are allowed&#xD;
&#xD;
                    4. dihydropyridine calcium channel blockers (amlodipine, diltiazem and&#xD;
                       verapamil are allowed)&#xD;
&#xD;
                    5. H2 antagonists and proton pump inhibitors (liquid and tablet antacids are&#xD;
                       allowed)&#xD;
&#xD;
                    6. midazolam, triazolam, alprazolam, terfenadine, astemizole, digoxin, coumarin&#xD;
                       derivatives, phenytoin, rifampin, HIV protease inhibitors, spironolactone,&#xD;
                       aliskiren, erythromycin or clarithromycin, cyclosporine or tacrolimus&#xD;
&#xD;
                    7. Subjects currently taking lipid lowering medications may be enrolled if the&#xD;
                       Investigator determines that the subject does not have any conditions that&#xD;
                       preclude cessation of lipid lowering treatment for up to 12 weeks. [All&#xD;
                       subjects will be required to discontinue all lipid lowering therapies during&#xD;
                       the 4 week Pre-Treatment Period and will then be randomized to receive&#xD;
                       either atorvastatin 10 mg or atorvastatin placebo during the first 8 weeks&#xD;
                       of the Treatment Period. All subjects will then receive atorvastatin 10 mg&#xD;
                       during weeks 8 to 16 of the Treatment Period.] Subjects may not be on any&#xD;
                       other lipid lowering agent through Visit 7 (Week 20) of the study.&#xD;
&#xD;
               9. History of HIV&#xD;
&#xD;
              10. Positive hepatitis B (HbsAg) or positive hepatitis C (Hepatitis C antibody) test&#xD;
                  during Screening&#xD;
&#xD;
              11. Liver function tests must not be above the following cut-offs: ALT and/or AST&#xD;
                  &gt;3.0X ULN, AP &gt;1.5X ULN and total bilirubin &gt;ULN. (If all LFTs are WNL and total&#xD;
                  bilirubin is elevated, a retest of direct and indirect bilirubin may be&#xD;
                  performed. Subjects with indirect total bilirubin up to 3X ULN (presumed&#xD;
                  Gilbert's syndrome) may be enrolled if all other LFTs are WNL.)&#xD;
&#xD;
              12. CK must not be &gt;2.5X ULN if not clearly related to recent exercise, injury or&#xD;
                  unusual activity&#xD;
&#xD;
              13. Creatinine must not be &gt;1.4 mg/dl in females and &gt;1.5 mg/dl in males.&#xD;
&#xD;
              14. Thyroid stimulating hormone level &gt;1.5X ULN&#xD;
&#xD;
              15. History of lactic acidosis&#xD;
&#xD;
              16. Known hypersensitivity to cosyntropin (ACTH) or any component of the formulation&#xD;
                  (mannitol or sodium chloride)&#xD;
&#xD;
              17. Known intolerance to statin drugs&#xD;
&#xD;
              18. Any other condition which increases the risk of participation in the trial in the&#xD;
                  opinion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherwyn Schwartz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes &amp; Glandular Disease Research Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Terence Hart</name>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <zip>35662</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genova Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Solutions</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Primary Care Clinic</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mills-Peninsula Helath Services</name>
      <address>
        <city>San Mateo</city>
        <state>California</state>
        <zip>94401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Research Goup University of Hawaii at Manoa</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton Diabetes Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AHS Oklahoma Physician Group</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Clinical Research Unit - Dr. Andrew Ahmann</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>927239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance CRU</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Glandular and Disease Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyell McEwin Hospital</name>
      <address>
        <city>North Western Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ECRU</name>
      <address>
        <city>Box Hill, Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>School of Medicine and Pharmacology</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keough Institute</name>
      <address>
        <city>Nedands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinology Research Unit</name>
      <address>
        <city>Herston Road</city>
        <zip>QLD 4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinology Department</name>
      <address>
        <city>St Leonards</city>
        <zip>NSW 2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourn Hospital</name>
      <address>
        <city>Victoria</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middlemore Hospital</name>
      <address>
        <city>Otahuhu</city>
        <state>Auckland</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lipid and Diabetes Research</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikaito Hospital</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Centre</name>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>June 28, 2007</study_first_submitted>
  <study_first_submitted_qc>June 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2007</study_first_posted>
  <last_update_submitted>November 11, 2008</last_update_submitted>
  <last_update_submitted_qc>November 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Bernice Welles, MD</name_title>
    <organization>DiObex, Inc.</organization>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

